BIO-TECHNE Corp
Financial highlights
| Metric | FY 06/30/26 | FY 06/30/25 | FY 06/30/24 | FY 06/30/23 | FY 06/30/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.2 | $1.2 | $1.2 | $1.1 | $1.1 |
| Operating income | $0.3 | $0.1 | $0.2 | $0.3 | $0.3 |
| Net income | $0.2 | $0.1 | $0.2 | $0.3 | $0.3 |
| Cash Flow Statement | |||||
| Free cash flow | $0.3 | $0.3 | $0.2 | $0.2 | $0.3 |
| Dividends | $<0.1 | $0.1 | $0.1 | $0.1 | $0.1 |
| Share repurchases | $<0.1 | $0.3 | $0.1 | $<0.1 | $0.2 |
Shares outstanding 156.8M · Free float 98.7%
Annual filing data through FY ended June 30, 2026; float as of September 21, 2026.
Coverage
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
September 24, 2026
Deals
Bio-Techne Shareholders Approve Merck KGaA's $11.3 Billion Cash Bid
June 25, 2026
Earnings Digest
BlackBerry Hits Cash Flow Milestone; M&A Hits Life Sciences, AI
June 25, 2026
Deals
Merck KGaA to Buy Bio-Techne in $11.3 Billion All-Cash Deal